Caricamento...
Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential
The clinical success of monoclonal antibody immune checkpoint modulators such as ipilimumab, which targets cytotoxic T lymphocyte-associated antigen 4 (CTLA-4), and the recently approved agents nivolumab and pembrolizumab, which target programmed cell death receptor 1 (PD-1), has stimulated renewed...
Salvato in:
| Pubblicato in: | Ther Adv Med Oncol |
|---|---|
| Autori principali: | , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2016
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4699263/ https://ncbi.nlm.nih.gov/pubmed/26753003 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758834015615514 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|